This significantly reduces the production of harmful and potentially harmful chemicals.The IQOS system heats tobacco but does not burn it.Philip Morris is now allowed to make the following claims with regards to IQOS: PMI applied for both, but the FDA decided only to grant the exposure modification. One refers to risk modification and the other to exposure modification. The MRTP process is a consequence of the 2009 Tobacco Control Act, which was strongly supported by Philip Morris. The agency cited scientific studies showing that switching completely to the IQOS system from cigarettes significantly reduces exposure to such chemicals.įor any tobacco product to claim reduced harm or exposure to toxic chemicals, the companies selling them must submit an MRTP at considerable cost in time and money. The FDA on Tuesday said that available evidence shows IQOS’s production of harmful and potentially harmful chemicals is lower that that of regular cigarettes. while it reviewed Philip Morris’s modified-risk product application. The FDA last year allowed IQOS, which is an electronic device that uses a tobacco plug, to be sold in the U.S. IQOS heats tobacco rather than burning it, a process seen as less harmful than smoking conventional cigarettes. Food and Drug Administration said Tuesday. can market its IQOS products as reducing consumers’ exposure to harmful chemicals found in cigarettes, the U.S. On Tuesday, the FDA announced Philip Morris can now claim that switching from smoking to IQOS significantly reduces exposure to the harmful chemicals found in cigarette smoke. Three years after Philip Morris International (PMI) submitted a modified risk tobacco product application (MRTP) to the Food and Drug Administration (FDA) for its IQOS tobacco heating system, the agency has finally made a decision.
0 Comments
Leave a Reply. |